Appointment dossier — Ovarian Carcinoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Ovarian Carcinoma
- Bevacizumab — Human evidence · 2 positive / 2 negative-mixed · PMID 38872480, 22529265, 39013199, 36603894
- Relacorilant — Human evidence · 2 positive · PMID 42334771, 40473448, 39032926
- Cisplatin — Human evidence · 1 positive / 1 negative-mixed · PMID 39549720, 39013199, 22330607
- Mirvetuximab Soravtansine — Human evidence · 1 positive / 1 negative-mixed · PMID 40508029, 30379722
- Trastuzumab Deruxtecan — Human evidence · 1 positive · PMID 39639215
- Trastuzumab-Deruxtecan (T-Dxd) — Human evidence · 1 positive · PMID 39639215
- Nivolumab †Rx — Human evidence · 0 positive · PMID 34593565
- Rucaparib — Human evidence · 0 positive / 1 negative-mixed · PMID 39266137, 39013199, 34593565
- Paclitaxel — Lab evidence · 1 positive / 1 negative-mixed · PMID 38884523, 39013199, 22591426
- Anastrozole — Review evidence · 0 positive · PMID 39013199
- Carboplatin — Review evidence · 0 positive · PMID 39013199
- Gemcitabine — Review evidence · 0 positive · PMID 39013199
- Liposomal Doxorubicin — Review evidence · 0 positive · PMID 39013199
- Niraparib †Rx — Review evidence · 0 positive · PMID 39013199
- Olaparib — Review evidence · 0 positive · PMID 39013199
- Tamoxifen — Review evidence · 0 positive · PMID 39013199
- Topotecan — Review evidence · 0 positive · PMID 39013199
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT05086692 · Phase 1 / Phase 2 — A Beta-only IL-2 ImmunoTherapY Study (United States)
- NCT07285044 · Phase 2 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas (United States)
- NCT07303894 · Phase 2 — A Study of Isoquercetin in People With Ovarian Cancer (United States)
- NCT03604315 · Phase 1 — Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF (United States)
- NCT06935344 — Evaluation of Polygenic Risk Score for Epithelial OVarian cancEr Risk Prediction: the PROVE Study (Italy)
- NCT06827353 — Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency (France)
- NCT05470920 — Genetic Testing Decision Aid (United States)
- NCT07612891 · Phase 1 / Phase 2 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor (China)
- NCT06545942 · Phase 1 — Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors (United States)
- NCT06215950 · Phase 1 — A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer (China)
- NCT07705035 · Phase 1 — DBC-664 in Adult Patients With Solid Tumors (United States)
- NCT06547840 · Phase 1 — A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha (United Kingdom)
- NCT07782164 — Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study) (Netherlands)
- NCT06824467 · Phase 3 — A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (United States)
- NCT02429687 · Phase 3 — TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors (China)
- NCT04520139 · Phase 1 / Phase 2 — Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT (United States)
- NCT04918186 · Phase 2 — Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (United States)
- NCT07311577 · Phase 2 — Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study (China)
Most-relevant first: trials that name Ovarian Carcinoma, then broader trials you may still qualify for. 644 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Interactions & safety to discuss
Not a complete check — a drug not listed here is not therefore safe. Show your pharmacist your full list.
- Niraparib †Rx × CYP1A2 inhibitors (high-stakes) — Monitor (low)
- Niraparib †Rx × P-gp substrates (high-stakes) — Monitor (low)
- Nivolumab †Rx × immunosuppressants (high-stakes) — Avoid (high)
- Nivolumab †Rx × Ipilimumab — Synergize (moderate)
- Niraparib †Rx × Bevacizumab — Synergize (low)
- Nivolumab †Rx × corticosteroids — Use For IrAE (low)
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- I've read that Bevacizumab has been studied in people for Ovarian Carcinoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Relacorilant has been studied in people for Ovarian Carcinoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Cisplatin has been studied in people for Ovarian Carcinoma — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT05086692), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?